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http://dx.doi.org/10.1016/j.ccell.2014.11.024SUMMARYDeregulated Myc transcriptionally reprograms cell metabolism to promote neoplasia. Here we show that
oncogenic Myc requires the Myc superfamily member MondoA, a nutrient-sensing transcription factor, for
tumorigenesis. Knockdown of MondoA, or its dimerization partner Mlx, blocks Myc-induced reprogramming
of multiple metabolic pathways, resulting in apoptosis. Identification and knockdown of genes coregulated
byMyc andMondoA have allowed us to definemetabolic functions required by deregulatedMyc and demon-
strate a critical role for lipid biosynthesis in survival of Myc-driven cancer. Furthermore, overexpression of a
subset of Myc and MondoA coregulated genes correlates with poor outcome of patients with diverse can-
cers. Coregulation of cancer metabolism by Myc and MondoA provides the potential for therapeutics aimed
at inhibiting MondoA and its target genes.INTRODUCTION
The MYC proto-oncogene family includes MYC that encodes
c-Myc, MYCN that encodes N-Myc, and MYCL that encodes
L-Myc. Myc proteins are bHLHZ transcription factors that regu-
late genes involved in growth and proliferation (Dang, 2012).
MYC genes are normally induced in response tomitogenic stimu-
lation. However, oncogenic activation occurs through events that
lead to overexpression of Myc proteins and failure to downregu-
late expression in response to appropriate physiological signals.
Deregulated Myc family proteins transcriptionally reprogram
cellular metabolism to facilitate the macromolecular synthesis
required for increased cell growth and proliferation. For example,Significance
Altered cellular metabolism is recognized as a hallmark of canc
mote tumorigenesis is critical for the development of effective t
vation of the oncogene MYC facilitates proliferation through m
larger Myc transcriptional network to tumorigenesis remains to
dent on the related network members MondoA and Mlx. The g
Myc-driven glutamine addiction and facilitates the reprogra
induced stress. This report identifies a role of the extended tran
and may lead to future anti-Myc therapeutic opportunities.
Cc-Myc induces aerobic glycolysis (the Warburg effect) by
enhancing glucose uptake and lactate production as well as
providing glycolytic intermediates for nucleotide, amino acid,
and lipid biosynthesis (reviewed in Dang, 2013; Vander Heiden
et al., 2009). While these processes divert carbon from the tricar-
boxylic acid (TCA) cycle and mitochondria, c-Myc also regulates
genes that enhance glutamine uptake and processing to fuel the
TCA cycle (Gao et al., 2009; Wise et al., 2008; Yuneva et al.,
2007); moreover, c-Myc stimulates mitochondrial activity
through induction of TFAM and other nuclear-encoded mito-
chondrial genes (Li et al., 2005). Recent work demonstrates
that c-Myc promotes lipid metabolism during cell cycle entry
(Morrish et al., 2010) and lymphomagenesis (Eberlin et al.,er. Understanding how cells modify their metabolism to pro-
herapeutic strategies to specifically target cancer cells. Acti-
etabolic reprogramming; however, the contribution of the
be explored. Here we show that deregulated Myc is depen-
lucose-responsive transcription factor MondoA/Mlx enables
mming of cancer cell metabolism while attenuating Myc-
scriptional network in regulating Myc’s oncogenic functions
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Figure 1. Synthetic Lethal Dependency of Deregulated Myc on MondoA
(A) SimplifiedMyc network schematic showing competition for heterodimerization partners (black lines with double arrowhead) and genomic E-Box loci between
network members (green and red lines indicate transcriptional activation and repression, respectively).
(B–E) Relative viability of P3C1 (B), CB660 and its immortalized (I-CB660) or Ras-transformed (T-CB660) derivatives (D), or neuroblastoma cell lines (E) or cell
number of P493-6 cells (C) transfected with indicated siRNAs normalized to the corresponding nonsilencing control (siCtrl). A pro-apoptotic siRNAmix (siDeath) is
included as a positive control for transfection efficiency. Shown are mean and SD (n = 3).
(F) Western blot analysis for MondoA, c-Myc, and N-Myc across the indicated cell lines under indicated conditions.
See also Figure S1 and Table S1.2014). Importantly, cells transformed by deregulatedMYC genes
are highly sensitive to metabolic stress induced by nutrient with-
drawal or inhibition of metabolic pathways (reviewed in Dang,
2011).
Myc proteins function within a transcription factor network
(Figure 1A; Conacci-Sorrell et al., 2014). These proteins form het-272 Cancer Cell 27, 271–285, February 9, 2015 ª2015 Elsevier Inc.erodimers with the small bHLHZ protein Max and bind to E-Box
sequences in DNA.Myc transcriptional activity is antagonized by
Mxd family proteins that compete with Myc for both Max and
E-Box binding. Expression of Mxd proteins often correlates
with cell cycle exit, growth arrest, and/or differentiation (Hooker
and Hurlin, 2006). In addition, a parallel, Myc-like network exists
centered aroundMlx (Billin and Ayer, 2006). Mlx heterodimerizes
with either MondoA or carbohydrate response element binding
protein (ChREBP). MondoA associates with the mitochondrial
outer membrane, where it can sense both glycolytic intermedi-
ates such as glucose 6-phosphate and mitochondrial metabo-
lites (Han and Ayer, 2013; Kaadige et al., 2009; Sloan and
Ayer, 2010). Metabolites promote nuclear localization of cyto-
plasmic MondoA protein, activating transcription of genes
involved in glucose metabolism (reviewed in O’Shea and Ayer,
2013). Moreover, Mlx heterodimerizes with a subset of Mxd fam-
ily proteins, thereby linking the Mlx and Max branches into a
larger transcription factor network (Figure 1A; Billin et al., 1999;
Meroni et al., 2000). This network is conserved throughout
metazoan evolution (McFerrin and Atchley, 2011), indicative of
collaboration between the nutrient-sensing Mondo and the
nutrient-utilizing Myc branches of the network.
Because environmental context can determine survival of cells
transformed by Myc family proteins, we reasoned that the
extended Myc-network is likely to be important in integrating
environmental cues and promoting tumor survival.
RESULTS
Synthetic Lethal Interaction between Deregulated Myc
and MondoA Loss of Function
To determine whether deregulated Myc depends on other tran-
scription factors within the Myc superfamily, we carried out a tar-
geted siRNA screen of the extended Myc network. The screen
used murine fibroblasts with doxycycline (dox)-inducible c-Myc
expression (cloneP3C1). Inductionof c-Myc (c-Myc-ON) resulted
in increased proliferation and apoptosis as well as loss of the dif-
ferentiationmarker Thy1.2 (Eischen et al., 2001; Evan et al., 1992;
Sridharan et al., 2009; Figures S1A–S1C available online). Our
most striking finding was that knockdown of MondoA and, to a
lesser extent, its obligate dimerization partner Mlx, revealed a
synthetic lethal (SL) effect in c-Myc-ON compared to c-Myc-
OFF cells (Figures 1B and S1D). Knockdown of ChREBP had no
effect because it is not expressed in P3C1 cells (Figure S1E).
To extend our observations on the dependency ofMyc overex-
pressing cells on MondoA/Mlx, we examined mouse embryonic
fibroblasts (MEFs) bearing homozygous deletions of eitherMlxip,
which encodes MondoA, or Mlx (D.E.A., P.F.C., P.A.C., and
R.N.E., unpublished data). Compared to the parental wild-type
cells, both Mlxip/ and Mlx/ primary MEFs display reduced
viability and higher levels of apoptosis upon c-Myc overexpres-
sion. Mlxip deletion also enhances c-Myc mediated apoptosis
in Large-T antigen immortalized fibroblasts, suggesting a p53-in-
dependent apoptotic process (Figure S1F and see below).
We next examined the effects of MondoA knockdown (KD) in a
panel of human cell types, in each case comparing cells without
and with overexpression of Myc. We found that KD of MondoA
using siRNA (siMonA) significantly reduces survival of the
P493-6 human B cell line expressing c-Myc (Figures 1C and
S1G). This SL effect was also observed with siMonA in human
neural stem cells (CB660) overexpressing c-Myc (CB660+c-
Myc) as well as their immortalized derivatives lacking p53 and
RB tumor suppressors (I-CB660+c-Myc) or transformed by the
additional expression of activated H-Ras (T-CB660+c-Myc) (Hu-
bert et al., 2013) (Figure 1D). Control cells were insensitive toCsiMonA, indicating that MondoA loss of function specifically in-
hibits survival of cells with deregulated c-Myc. MondoA silencing
also inhibits the growth of colon cancer cell line HCT116, hepa-
tocellular carcinoma cell line HEPG2, and ovarian cancer cell line
TOV1112D, all of which express high levels of c-Myc (Fig-
ure S1H). Importantly, siRNA against Mlx also elicited the same
response in all cells tested (data not shown).
MYCN amplification is observed in approximately 25% of hu-
man neuroblastomas and correlates with poor outcome (Brodeur,
2003; Huang and Weiss, 2013). Therefore, we examined the
requirement of deregulated N-Myc for MondoA using a retroviral
vector to achieve stable MondoA KD (Kaadige et al., 2009) in hu-
man neuroblastoma cell lines. Upon MondoA silencing, MYCN
amplified IMR32, and SK-N-BE cells and Tet21N cells overex-
pressing N-Myc displayed reduced viability compared to the
MYCN nonamplified SH-SY-5Y or the Tet21N cells in which N-
Myc is not overexpressed (Figure 1E). Reduction of MondoA pro-
tein levels following knockdown is shown in Figure S1I.We did not
detect changes inMyc protein levels after MondoA silencing, indi-
cating that loss of MondoA does not inhibit cell proliferation by
reducing Myc expression (see Figures S2A, S2H–S2J). However,
c-Myc or N-Myc induction enhances MondoA mRNA (Figures
S1J and S1K) and protein levels in both cytoplasm and nucleus
(Figures 1F andS1L) in Tet21NandP493-6 cells. This is consistent
with our chromatin immunoprecipitation data for N-Myc (Fig-
ure S1M), aswell asdata from theENCODEdatabase (not shown),
showing that c-Myc binds the MondoA promoter region.
BecauseMondoA would be expected to compete with several
Mxd transcription factors for binding toMlx,we surveyed expres-
sion levels of Mxd1, Mxd4, and Mnt upon N-Myc activation in
Tet21N cells. N-Myc overexpression reduces c-Myc and Mxd4
protein expression while increasing Max, Mlx, and MondoA pro-
teins (Figure S1N). Consistent with this, the expression of the
MondoA target geneTxnip increasesuponN-Mycactivation (Fig-
ure S1O). Our experiments suggest that deregulated Myc alters
theMax/Mlxnetwork toenhanceMondoA/Mlx transcriptional ac-
tivity and requires MondoA/Mlx for survival and proliferation.
MondoA Suppresses Myc-Induced Apoptosis in
Neuroblastoma
To study functional interactions between N-Myc and MondoA,
we used the Tet21N cell line (Lutz et al., 1996). Tet21N cells in
the presence of dox (N-Myc-OFF) express endogenous c-Myc
and proliferate but are nontumorigenic. Following dox with-
drawal, N-Myc is induced (N-Myc-ON) in Tet21N cells and cells
display increased proliferation and growth in soft agar and as
xenografts (Kim et al., 2007; Wasylishen et al., 2014). We as-
sessed proliferation, the cell cycle, and apoptosis in Tet21N cells
under four conditions: siCtrl or siMonA with and without dox.
Transient siMonA blocked proliferation of the Tet21N N-Myc-
ON cells, while having little or no effect on the N-Myc-OFF cells,
compared to siCtrl (Figure 2A). Each of the four individual siRNAs
efficiently silences the expression of MondoA and only inhibits
the growth of N-Myc-ON cells, indicating the phenotype we
observed is a result of MondoA inactivation (Figure S2A). While
siMonAmarginally reduces the percentage of cells in S phase in-
dependent of N-Myc levels, there is a striking accumulation of
sub-G1 cells in the siMonA N-Myc-ON cells, indicative of
apoptosis (Figures 2B and 2C). MondoA KD also blockedancer Cell 27, 271–285, February 9, 2015 ª2015 Elsevier Inc. 273
Figure 2. Loss of MondoA Blocks N-Myc-Induced Proliferation and Tumorigenesis while Potentiating Apoptosis Both In Vitro and
In Vivo.
(A) Growth curves of Tet21N cells, with or without N-Myc overexpression, treated with either siCtrl or siMonA. Shown are mean and SD (n = 3).
(B) Cell cycle analysis of cells from (A) at day 3.
(C) Time course quantification of sub-G1 cell population. Shown are mean and SD (n = 3).
(D) Western blot analysis for the indicated proteins in Tet21N cells with or without N-Myc overexpression at day 3 post-transfection of either siCtrl or siMonA.
(E and F) Representative colony morphology (E) and quantification of colony formation (F) of neuroblastoma cells in soft agar at day 14 after plating. Scale bar
represents 20 mm. CFU, colony-forming units. Shown are mean and SEM (n = 9).
(legend continued on next page)
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Figure 3. Transcriptional Coordination be-
tween N-Myc andMondoA Regulates Meta-
bolism and Proliferation
(A) Heatmap generated by TreeView representing
the median Z-score of all genes whose expression
is altered for each condition.
(B) Log fold change (Log-FC) of all, N-Myc upre-
gulated, and N-Myc downregulated probes in the
presence or absence of MondoA. Shown is a box
plot indicating maximum (upper line), third quartile
(top of box), median (line in box), first quartile
(bottom of box), and minimum (lower line).
(C) Venn diagram of N-Myc (in the presence of
MondoA) and MondoA (in the presence of N-Myc)
regulated genes.
(D) Gene ontology analysis: genes upregulated by
N-Myc (white), MondoA (gray), or both (striped) for
each category are shown.
(E) Global expression profile of N-Myc and
MondoA cooperatively upregulated genes among
the four conditions. Genes encoding metabolic
regulator as indicated with colored lines.
(F) Gene ontology analysis of MondoA regulated
genes (N-Myc-ON condition)
(G) Global expression profile of MondoA upregu-
lated genes involved in lipid and glucose meta-
bolism as indicated with colored lines.
See also Figure S3.expression of its target gene TXNIP (Figures 2D and S2B; Stoltz-
man et al., 2008), and suppressedmechanistic target of rapamy-
cin (mTOR) activity (Figure 2D). We also detected increased
levels of p53 and p21 with siMonA, which are further increased
after N-Myc activation (Figure 2D). Our data suggest MondoA
suppresses stress associated with N-Myc deregulation and en-
sures cell cycle progression and survival.
The tumorigenic potential of Tet21N cells stably expressing
either shCtrl or shMonA was first assessed by soft agar assays.
While shCtrl N-Myc-ON cells form numerous colonies, shMonA
N-Myc-ON cells formed fewer and smaller colonies (Figures 2E
and 2F). MondoA silencing also reduced the growth of N-Myc-
amplified cell lines in soft agar (Figure 2F). Importantly, the dimin-
ished cloning efficiency in shMonAN-Myc-ON cells and reduced
viability of HCT116 cells expressing shMonA were rescued by
the expression of an shRNA-resistant MondoA (Figures 2F,(G) Subcutaneous growth of Tet21N cells stably expressing either shCtrl or shMonA in Nu/Numice and a repre
SEM (n = 10).
(H) Final tumor weight and representative image of tumors at endpoint. Shown are mean and SEM (n = 10).
(I) Quantification of immunohistochemistry positivity for Ki67 and cleaved-caspase 3 (CC3) in tumors from (G
See also Figure S2.
Cancer Cell 27, 271–285S2C, and S2D). Finally, ectopic expres-
sion of MondoA in knockdown cells sup-
presses N-Myc-mediated activation of
p53 and p21 (Figure S2E), and restores
expression of the MondoA target gene
TXNIP (Figure S2F), ruling out off-target
effects of either shRNA or siRNA.
We also performed subcutaneous
xenograft of Tet21N N-Myc-ON cells sta-
bly expressing either shCtrl or shMonA.We observed reduced tumor size and tumor weight of cells
expressing shMonA (Figures 2G and 2H) due to both loss of pro-
liferation and activation of apoptosis (Figures 2I and S2G). Both
N-Myc protein stability in the Tet21N cells (Figure S2H) and
abundance in lysates derived from the xenografts (Figure S2I)
are independent of MondoA. Very similar SL interactions were
obtained in the P493-6 human lymphoma line (Figures 1C and
S2J). We conclude that MondoA is broadly required for down-
stream functions of Myc in tumor growth and survival in vitro
and in vivo.
N-Myc and MondoA Coordinately Regulate Expression
of Growth-Promoting Genes
To find out if MondoA loss affects N-Myc functions, we
compared transcriptional changes induced by N-Myc activa-
tion in the presence or absence of MondoA (Figures 3A andsentative animal at endpoint. Shown are mean and
Scale bar represents 1 cm.
) Shown are mean and SEM (n = 12).
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S3A–S3C). Overall, the N-Myc-induced changes in gene expres-
sion are highly correlated independent of MondoA levels (Fig-
ure S3B). Moreover, MondoA knockdown does not alter the
levels of histone H4 acetylation observed upon N-Myc induction
(Figure S3D), indicating MondoA functions in conjunction with
Myc, but does not fundamentally alter N-Myc activity.
However, whereas the general transcriptional activity of
N-Myc is similar in the presence or absence of MondoA, the
magnitude of change for both N-Myc activated and repressed
genes is significantly attenuated in the siMonA condition
compared to siCtrl (Figure 3B). Interestingly, after normalizing
gene expression values to the siMonA/N-Myc-OFF condition
and comparing the relative contributions of N-Myc and MondoA
alone, we observe a trend in which both transcription factors
similarly up- or downregulate a large number of genes in com-
mon (Figure S3E). Specifically, we identified 553 and 587 genes
significantly upregulated and downregulated, respectively, when
both N-Myc and MondoA are present (Figures 3A and 3C).
To assess the functional relevance of these transcriptional
profiles, we used gene ontology analysis of the gene sets individ-
ually and cooperatively regulated by N-Myc and MondoA (false
discovery rate [FDR] adjusted p < 0.05). N-Myc primarily drives
the expression of genes promoting cell proliferation and growth
(Figure 3D, white bars). However, N-Myc also requires MondoA
to maximally upregulate a large number of genes involved in
these processes (Figure 3D, striped bars). The relative expres-
sion levels of all cooperatively upregulated genes among the
four conditions are shown in Figure 3E. Interestingly, among
these are several genes critical for nucleotide biosynthesis,
amino acid metabolism and transport, mitochondrial biogenesis
and function, and the TCA cycle.
We also find that silencing of MondoA independent of N-Myc
leads to lower expression of genes involved in oxidation-reduc-
tion reactions, cholesterol and steroid metabolism, as well as
components of the endoplasmic reticulum, extracellular matrix,
peroxisomes, and lysosomes (Figure 3F, gray bars). In particular,
MondoA depletion leads to a strong decrease in SREBP1 and
SCD expression, as well as a lesser reduction in FASN and
PCK2, which encode enzymes involved in lipid and glucose
metabolism, respectively (Figure 3G). Hence, N-Myc, individually
and in cooperation with MondoA, controls the expression of a
large set of genes involved in proliferation, metabolism, and
growth, whereas MondoA additionally regulates complementary
pathways such as lipid and sterol biogenesis.
There may be several mechanisms for the cooperative tran-
scriptional regulation by N-Myc and MondoA. To determine
whether both factors co-occupy promoters of coregulated
genes we tested if N-Myc and MondoA bind to the TXNIP pro-
moter, a bona fideMondoA target that contains three noncanon-
ical E-boxes. Results show that both factors bind to the TXNIP
promoter and that maximum binding of both N-Myc and
MondoA requires the simultaneous presence of both factors
(Figure S3F and Discussion).
Expression of Myc/MondoA-Dependent Genes Involved
inMetabolism Is Required for Survival of Neuroblastoma
Cells
Our data show that a significant fraction of genes regulated by
N-Myc and MondoA are linked to metabolic activities (Figures276 Cancer Cell 27, 271–285, February 9, 2015 ª2015 Elsevier Inc.3D–3G). We used qRT-PCR and immunoblot analyses to assess
expression of a subset of genes under the four conditions used in
the microarray study, focused on those affecting multiple meta-
bolic pathways, and found that all genes analyzed require either
N-Myc/MondoA or MondoA for maximal expression (Figures 4A
and S4A). The expression of these genes was similarly affected
by silencing of the MondoA heterodimerization partner Mlx in
Tet21N cells, consistent with the notion that changes in expres-
sion we observed are a direct consequence of the lack of
MondoA-Mlx heterodimers (Figure S4B). Interestingly, silencing
of either MondoA or Mlx results in the loss of expression of
both proteins, indicating that heterodimerization promotes com-
plex stability (Figure S4B).
Because we also observe synthetic lethality in P493-6 B cells,
we queried http://www.oncomine.org for data sets of B cell ma-
lignancies (Basso et al., 2005; Zhang et al., 2013). We found a
correlation between c-Myc, Mlx (in one data set), and many
target genes in both Burkitt lymphoma and other B-cell malig-
nancies as well as neuroblastoma (Table S1) (Janoueix-Lerosey
et al., 2008; Wang et al., 2006), consistent with the notion of
similar transcriptional reprogramming of metabolism by the co-
ordinate action of Myc-Max and MondoA-Mlx arms of the
network. Using MondoA or Mlx null primary MEFs, we found
that expression of Slc1A5 and Tomm20, both of which are core-
gulated in the Tet21N cells, depends on both Myc and MondoA
(Figure S4C), implying that c-Myc and MondoA display a similar
mode of coregulation in primary cells.
We also confirmed that N-Myc requires both 25 mM glucose
and MondoA to fully activate the expression of the glutamine
(Gln) transporter Slc1A5, suggesting that glucose-responsive
transcriptional activity of MondoA coordinates glucose availabil-
ity with Gln uptake (Figure 4B). To determine whether cellular
metabolism is affected by MondoA knockdown in the Tet21N
cells, we measured carbon source uptake using radiolabeled
Gln or 2-deoxyglucose. A notable increase in Gln uptake was
observed upon N-Myc activation, which was inhibited by
shMonA treatment in both the N-Myc-ON Tet21N cells (Fig-
ure 4C) and in c-Myc overexpressingMEFs (Figure S4D). Consis-
tent with the glucose dependency of Slc1A5 expression,
maximal N-Myc-induced Gln uptake was also glucose-depen-
dent (Figure S4E). In contrast, N-Myc expression or MondoA
knockdown produced only a modest increase in 2-deoxyglu-
cose uptake and no significant difference was observed be-
tween control and SL conditions (Figure S4F). Furthermore,
although extracellular acidification rate was not significantly
affected by N-Myc expression or shMonA (Figure S4G), MondoA
loss prevented the N-Myc driven increase in Gln-dependent
oxygen consumption rate (Figure 4D), confirming that MondoA
loss in cells expressing N-Myc results in fundamental changes
in cellular Gln metabolism.
Decreased expression of transporter genes may account, at
least in part, for diminished Gln uptake and viability upon
MondoA loss (Figures 4A and S4A). As previously shown, knock-
downs of either Gln importer Slc1A5 or antitransporter Slc3A2
resulted in decreased activity of mTOR, as measured by ribo-
somal protein S6 phosphorylation (p-RpS6) (Figure 4E) (Dura´n
et al., 2012; Nicklin et al., 2009). However, only Slc1A5 silencing
reduced Gln uptake, arguing that loss of Slc3A2 does not affect
cell viability and mTOR signaling by preventing Gln uptake
Figure 4. N-Myc and MondoA Coordinately
Regulate Metabolic and Mitochondrial Tar-
gets in Tet21N Cells
(A) Western blot analysis of a subset of N-Myc and
MondoA coordinately regulated or MondoA-
dependent targets.
(B) Western blot analysis of Tet21N cells under
the indicated conditions in response to glucose
stimulation.
(C) Glutamine (Gln) uptake assay of Tet21N cells
with the indicated treatment. Shown are mean and
SD (n = 3).
(D) Oxygen consumption rate (OCR) assay of
Tet21N cells with the indicated treatment. Shown
are mean and SD (n = 3).
(E) Western blot analysis of the indicated proteins
in siCtrl cells or cells with KD of Slc1A5 or Slc3A2.
(F) Cells expressing indicated proteins or vector
control were transfected with siCtrl or siMonA and
viable cells were enumerated by trypan blue
exclusion after 4 days. Shown are mean and SD
(n = 3).
(G) Viability of cells in the presence or absence of
Myc expression (normalized to the relative control
siRNA) 4 days after transfection with the indicated
siRNA. Shown are mean and SD (n = 3). The red
line indicates the control is set to 1.
See also Figure S4 and Table S1.(Figure S4H). Importantly, while overexpression of Slc1A5 en-
hances Gln uptake (Figure S4I), neither Slc1A5 nor Slc3A2 over-
expression rescues cell viability (Figure 4F). Therefore, reduced
Gln uptake is not solely responsible for the observed SL
phenotype.
Loss of MondoA attenuates the expression of genes involved
in other metabolic pathways; therefore, we asked how the indi-
vidual KD of coregulated or MondoA-dependent genes influ-
ences Tet21N cell survival. As shown in Figure 4G, siRNAs
against 15 out of 21 selected targets were significantly more effi-
cient at killing cells overexpressing N-Myc. Depletion of a subset
of these targets in CB660 human NSCs confirmed that the single
gene KD phenotype is Myc-specific in different cell lines
(Figure S4J).
Inhibition of Myc/MondoA-Dependent Genes Induces
P53-Independent Synthetic Lethality with
Deregulated Myc
Because the activity of mTOR and p53 are often inversely corre-
lated under stress conditions (Feng and Levine, 2010), we eval-Cancer Cell 27, 271–285uated whether the individual silencing of
other Myc SL metabolic genes affects
p-RpS6 and p21 levels, as indicators of
mTOR and p53 activity, respectively.
While only inactivation of Pfas, Cbs, or
Pck2 results in mTOR inhibition, all
knockdowns induce p21 to varying levels
(Figure 5A). This suggests that p53
senses the activity of multiple Myc- and
MondoA-regulated pathways.
To evaluate the response of Tet21N
cells to p53 activation, we used theMDM2 antagonist Nutlin-3a, which strongly induces both p53
and p21 and inhibits growth of both N-Myc-OFF and -ON cells
(Figures 5B and 5C). However, Nutlin-3a treatment does not
stimulate significant caspase activity in siCtrl cells, regardless
of N-Myc status (Figure 5C), indicating that p53 activation pro-
motes cell cycle arrest but not apoptosis in these cells.
Conversely, loss of MondoA alone promotes caspase activity
in N-Myc-ON cells, which is further enhanced by Nutlin-3a
treatment (Figure 5C). This implies that MondoA silencing in
N-Myc-ON cells induces apoptosis and that p53 activation
only contributes to apoptosis following loss of MondoA. Impor-
tantly, we observe caspase activation only when N-Myc is over-
expressed. Furthermore, complete knockdown of p53 in the
N-Myc-ON cells only partially rescues viability with siMonA (Fig-
ure 5D). Moreover, while p53 KD re-establishes RpS6 phosphor-
ylation, it does not reestablish expression of Myc and MondoA
target genes Pfas and Tomm20, indicating that the reduction in
mTOR activity is a consequence of apoptosis and not the cause
of the SL phenotype (Figure S5A). Moreover, HCT116 cells (Fig-
ures 5E and S5B), or CB660 cells (Figure S4J) and MEFs, February 9, 2015 ª2015 Elsevier Inc. 277
Figure 5. MondoA Suppresses N-Myc-Induced Metabolic Stress
(A) Western blot analysis of Tet21N under the indicated conditions transfected with the indicated siRNA.
(B) Western blot analysis of Tet21N cells for the indicated proteins (/+ N-Myc and /+ nutlin-3a).
(C) Cell viability (Cell Titer Glo) and apoptosis (Caspase-Glo reagent) quantification after nutlin-3a treatment under the indicated conditions. Shown are mean and
SEM (n = 5).
(D) Viability assay of Tet21N cells expressing either a control or a p53 shRNA. Shown are mean and SD (n = 3).
(E) Viability assay of HCT116 p53+/+ and p53/ cells after knockdown of MondoA, Mlx, and Myc/MondoA target genes. Shown are mean and SEM (n = 5).
(F) Western blot analysis of the indicated apoptosis-related proteins in the Tet21N cells (/+ N-Myc) under siCtrl or siMonA treatment.
(G) Tet21N cells (/+ N-Myc) expressing vector control (same as in Figure 4F) or BCL2were transfected with siCtrl or siMonA and viable cells were enumerated by
trypan blue exclusion after 4 days (left) and western blot for Bcl2. Shown are mean and SD (n = 3).
See also Figure S6.
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overexpressing c-Myc (Figure S5C), are equally sensitive to loss
of MondoA, Mlx, or a number of critical Myc/MondoA targets, in-
dependent of p53 status. In addition, siMonA also results in the
loss of Slc1A5, Pfas and Tomm20 expression and decreased
Gln uptake independent of p53 in HCT116 cells (Figures S5D
and S5E), confirming that MondoA loss promotes apoptosis, at
least in part, through a p53-independent mechanism.
Wealso find that loss ofMondoA (Figure 5F) orMlx (Figure S5F)
leads to downregulation of the prosurvival Bcl2 protein and pro-
motes the appearance of the proapoptotic, truncated forms of
Bid and Bax (tBid and tBax) and cleaved Parp, only in N-Myc-
ON cells. These data indicate that N-Myc overexpression is
required to promote apoptosis in the absence of MondoA
through an intrinsic apoptotic pathway. However, enforced
expression of Bcl2 was not sufficient to rescue viability in
N-Myc-ON, siMonA cells (Figure 5G). These results prompted
us to search for alternative MondoA-dependent metabolic path-
ways required for N-Myc-induced tumorigenesis.
Metabolic Profiling Reveals that N-Myc and MondoA
Coordinately Regulate Anaplerotic and Cataplerotic
Reactions of the Tricarboxylic Acid Cycle
We used LC-MS based metabolomic analysis to survey 139 sol-
uble metabolites representing precursors and intermediates of
major anabolic and catabolic pathways (see Supplemental
Experimental Procedures). As shown in Figure 6A, we detected
significant changes in metabolite abundance among the four
conditions. Metabolite set enrichment analysis reveals that
N-Myc activation broadly modifies the cellular metabolic profile,
promotes profound changes in amino acid metabolism and re-
sults in enhanced abundance of precursors for de novo purine
and lipid biosynthesis (Figure 6B; blue bars). Importantly, the
majority of metabolite set enrichment analysis categories en-
riched by N-Myc induction display diminished significance
upon siMonA treatment in our SL condition (Figure 6B, orange
bars). Consistent with the observed cooperative transcriptional
regulation of metabolic genes, we observe that maximal
enrichment of certain metabolites, such as the nucleotide sugar
ribose-5-phosphate and the isoprenoid geranyl-pyrophosphate
depends on both N-Myc and MondoA. We also observe dimin-
ished levels of glutamate (Glu) and malate (Mal) and a 5–fold in-
crease in citrate (Cit) upon MondoA silencing (Figure S6A and
data not shown). These data indicate alterations in the TCA cycle
as a result of mitochondrial dysfunction, consistent with our
observations of diminished mitochondrial content and activity,
and enhanced reactive oxygen species production (Figures
S6B and S6C).
Because we observed diminished Gln uptake and alterations
in abundance of TCA cycle intermediates, we directly tested
how Gln metabolism is modified by N-Myc and MondoA. We
used a gas chromatography-mass spectrometry (GC-MS)
method (Du et al., 2013) to trace the contribution of uniformly
labeled 13C5-Gln toGlu, a-ketoglutarate (aKG),Mal, Cit, pyruvate
(Pyr), and lactate (Lac). We chose 24 hr labeling to account for
metabolites upstream and downstream of the TCA cycle. Fig-
ure 6C shows that loss of MondoA results in a decreased
N-Myc dependent fractional contribution of 13C5-Gln to metabo-
lite pools downstream of the glutaminase reaction, as indicated
by decreased metabolism of Gln (mass of glutamine + 5(13C) =Cm+5) to Glu (m+5), aKG (m+5), Mal (m+4) but, paradoxically
not TCA-derived Cit (m+4). We did not detect 13C5-Gln contrib-
uting to either Pyr or Lac (data not shown), indicating that Gln
is filling the TCA and not being converted to Pyr, via cytosolic
malic enzyme, then, via lactate dehydrogenase A, to Lac.
To directly test if reduced glutaminolysis and mitochondrial
activity are responsible for the synthetic lethal phenotype, we
evaluated the response of Tet21N cells to both nutrient with-
drawal and metabolic perturbing agents (Table S2). These cells
are both glucose- and Gln-dependent, sensitive to common glu-
taminolysis perturbing agents, such as the nonspecific transam-
inase inhibitor aminooxyacetate (Szabo et al., 2013; Wise et al.,
2008), the OXPHOS complex I inhibitor metformin, or the Pck1/
Pck2 inhibitor 3-mercaptopicolinic acid, and sensitive to oxida-
tive stress induced by H2O2. We also tested pathway-specific
metabolites for their ability to rescue loss of viability induced
by treatment with inhibitors or siMonA. While none of the rescue
agents can substitute for glucose or Gln, each specific inhibitor
can be rescued by metabolites downstream of the inhibited
pathway. Similar sensitivities to these inhibitors were observed
in HCT116 cells, independent of p53 status (Table S2 and data
not shown).
Importantly, none of the agents used to rescue impaired gluta-
minolysis, such as dmKG, Pyr, or enforced Slc1A5 or Bcl2
expression (Wise et al., 2008; Yuneva et al., 2007) is sufficient
to rescue loss of MondoA (Table S2 and data not shown). There-
fore, we ruled out a solely anaplerotic defect, and interrogated
pathways downstream of the TCA cycle. As noted, Cit accumu-
lates by 6-fold in the SL condition, as confirmed by GC-MS of
total Cit (Figure 6D). Because Cit is produced from aKG either
through the TCA cycle (producing m+4 Cit) or via an isocitrate
dehydrogenase-mediated reductive carboxylation (producing
m+5 Cit) (Figure S6D), we quantified m+5 Cit by GC-MS. We
find a dramatic reduction in the m+5 Cit fraction under the SL
condition (Figure S6E), indicating that, while the fate of Gln-
derived aKG ismodified under our four conditions, the increased
Cit content is not due to enhanced synthesis. Thus the marked
accumulation of Cit could result from its diminished downstream
utilization for de novo fatty acid or isoprenoid biosynthesis.
Consistent with this hypothesis, we observed that loss of
MondoA results in the downregulation of Srebp1, Fasn, and
Scd, (Figure 4A) all of which participate in the lipid biosynthesis
pathway. Because Cit can be converted to acetyl-coA for
de novo fatty acid synthesis (Figure S6D), we tested if Gln-
derived carbons contribute to lipid and if loss of MondoA impairs
lipid biosynthesis. To this end, we used a lipid extraction protocol
and GC-MS (Metallo et al., 2012) for tracing Gln-derived carbons
to palmitate (C16:0) in the free fatty acid pool 48 hr after the addi-
tion of 13C5-Gln. While N-Myc cooperates with MondoA to pro-
vide Gln as anaplerotic substrate to generate Cit, MondoA is
further required to convert Cit into fatty acids because the total
fraction of labeled palmitate (sum of m+2(N) palmitate) drops
from about 20% to less than 15% of the pool upon MondoA
silencing, independent of N-Myc (Figures 6E and S6F). Consis-
tent with loss of Fasn expression, the fraction of labeled palmi-
tate (m+4 to m+12) is significantly diminished (Figure 6E).
Deletion of Mlx in MEFs expressing endogenous Myc also
leads to decreased expression of MondoA, Fasn, and other tar-
gets and reduced lipid content, but does not induce apoptosisancer Cell 27, 271–285, February 9, 2015 ª2015 Elsevier Inc. 279
Figure 6. Metabolomic Profiling of N-Myc and MondoA Regulated Pathways
(A) Heatmap depicting normalized and log-transformed metabolomic survey of 139 soluble metabolites under the four conditions. Color code for bar graphs in
(A–E): white, siCtrl; blue, siCtrl+N-Myc; green, siMonA; and orange, siMonA+N-Myc.
(B) Metabolite set enrichment analysis of metabolite data from each condition compared to siCtrl. Shown is the Log p Value for enrichment with p = 0.05
indicated by the red line at 1.34.
(C) GC-MS tracing of 13C5-Gln for 24 hr in the Tet21N cells (/+N-Myc) with siCtrl or siMonA treatment with the quantification of the mass isotopomers
downstream of Gln indicated. Shown is mean and SD (n = 3).
(D) Quantification of total citrate (Cit) as in (C), normalized to relative cell number. Shown is mean and SD (n = 3).
(legend continued on next page)
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(Figures S6G–S6J, and data not shown). Therefore diminished
de novo fatty acid biosynthesis observed in the synthetic lethal
condition is not a consequence of apoptosis but the metabolic
response to the loss of MondoA-Mlx transcriptional activity
and target gene expression.
To confirm the dependency of N-Myc-overexpressing cells on
lipid biosynthesis for viability, we tested the sensitivity of Tet21N
cells to the Fasn inhibitor C75 and the farnesyl diphosphate
synthase inhibitor zoledronic acid (ZOL), which blocks geranyl-
pyrophosphate production. Consistent with the siRNA results,
N-Myc-overexpressing cells are significantly more sensitive to
these inhibitors and there is no effect on viability of N-Myc-
OFF cells when treated with the half-maximal inhibitory concen-
tration of N-Myc-ON cells (Figure S6K). Furthermore, C75, but
not ZOL, treatment synergizeswith siMonA to hyperactivate cas-
pase (Figures 6F and S6L), suggesting a sensitization to loss of
FASN activity and consistent with decreased flux into palmitate.
Similarly, siRNA-mediated silencing of Fasn or Scd enhances
apoptosis in N-Myc-ON cells (Figure S6M). In addition, while
the effect of ZOL treatment can be rescued by the downstream
metabolite geranylgeraniol (Table S2), this metabolite fails to
rescue loss of viability in siMonA N-Myc-ON cells, indicating
that inhibition of the isoprenoid pathway is not the causal event
of our SL phenotype. Because C75 treatment can be rescued
by oleate (C18:1) (Table S2), we tested if oleate can rescue
viability of siMonA N-Myc-ON cells. As shown in Figures 6G,
6H, and S6N, oleate suppresses activation of stress upon
siMonA treatment and partially restores cell viability, thus placing
the failure of lipid biosynthesis upstream of the cascade of
stress-inducing events leading to the SL phenotype.
ASubset of Synthetic Lethal GenesCorrelateswith Poor
Outcome in Several Cancers
Our data indicate that Myc and MondoA coordinately and inde-
pendently enhance the expression of multiple metabolic genes
to promote tumorigenesis (Figure 7A). If so, high expression of
several of these genes in human cancers would be predicted
to correlate with poor prognosis. Using the cumulative expres-
sion of MLXIP, CAD, TFAM, CBS, SCD, PFAS, SLC3A2, and
SLC1A5, we calculated the overall survival of patients with
different types of cancer and found that, in most cases, patients
with high expression of the signature (top 20%, red) have poorer
prognosis compared to those with low expression (bottom 20%,
blue; the remaining 60% are shown in gray) (Figure 7B). How-
ever, while the difference between high- and low-expressing
gene signatures is significant in neuroblastoma, liver hepatocel-
lular carcinoma and lung squamous cell carcinoma and lung
adenocarcinoma, it is onlymarginally significant in acutemyeloid
leukemia and colon adenocarcinoma and not significant in
breast invasive carcinoma. This reflects the inherent heterogene-(E) GC-MS tracing of 13C5-Gln for 48 hr in the Tet21N cells as in (C), with cont
topomers. The de novo fatty acid synthesis pathway is indicated, with enzymes
(F) Relative caspase activity of Tet21N cells (/+N-Myc) transfectedwith siCtrl or s
measured by Caspase-Glo reagent. Shown is mean and SEM (n = 5).
(G) Tet21N cells were transfected with the indicated siRNA and treated with eithe
post-transfection and viability was assessed by Cell-Titer Glo reagent at 96 hr. S
(H) Western blot analysis of cells treated as in (G) for the indicated proteins. All p
See also Figure S6 and Table S2.
City of cancer and it is consistent with a recent report demon-
strating that c-Myc overexpression elicits distinct metabolic pro-
grams in different tissues (Yuneva et al., 2012).
DISCUSSION
Proliferation and metabolism are precisely coordinated pro-
cesses during normal cell growth and division and are frequently
deregulated in cancer. A unique property of the Max/Mlx
network is its capacity to sense and respond tomitogenic signals
and nutrient availability (Diolaiti et al., 2014; O’Shea and Ayer,
2013). In this study, we provide evidence that the MondoA-Mlx
heterodimer is required for Myc-driven transcriptional reprog-
ramming of cellular metabolism and tumor growth. We show
that MondoA/Mlx coordinates glucose sensing with Gln utiliza-
tion and subsequent downstream biosynthesis required for
Myc to promote hyperproliferation. Previous work has demon-
strated a critical role for Gln in survival of Myc-driven cancers
(Dang, 2011; Qing et al., 2012; Shachaf et al., 2007; Wise
et al., 2008; Yuneva et al., 2007). Here, we show that MondoA
loss suppresses Myc-induced Gln uptake, Gln-dependent
mitochondrial activity, and Gln-derived lipid biosynthesis, thus
resulting in apoptosis. In support of our findings, MondoA was
reported to be overexpressed in acute lymphoblastic leukemia,
and its silencing prevents tumor cell growth (Wernicke et al.,
2012). The SL phenotype described here places MondoA atop
a transcriptional cascade that coordinately regulates multiple
metabolic pathways critical for Myc-driven tumor survival.
Impairment of Myc/MondoA downstream metabolic effectors
identified in this study has permitted us to define SL interactions
specific to deregulated Myc. These include those involved in
glucose, amino acid, nucleotide, mitochondrial function, and
lipid metabolism.While Myc’s connection with, and dependency
upon, enhanced glycolysis, glutaminolysis, and mitochondrial
activity are well known, a role for Pck2, a gluconeogenic enzyme,
reveals a requirement of Myc for a bidirectional pathway. Recent
reports demonstrating the necessity for Pck2 activity in both lung
and breast cancer cells under nutrient limitation (Leithner et al.,
2014; Me´ndez-Lucas et al., 2014) are consistent with MondoA-
Mlx function as a nutrient-responsive factor to regulate survival.
We also observed impairment of lipid metabolism in our SL
condition. While the MondoA family member ChREBP has
been linked to glucose-derived lipogenesis in cancer cells
(Tong et al., 2009), ChREBP has not been reported to alter gluta-
minolysis and its requirement for Myc-driven tumorigenesis
remains untested. Our data support nonredundant roles for
MondoA and ChREBP, as siRNA against MondoA (as well
against Mlx) kills ChREBP-expressing cells.
Multiple studies have shown that inhibition of Acaca, Fasn, or
Scd activity (Zaidi et al., 2013) and loss of Srebp1 (Griffiths et al.,ribution of 13C5-Gln-derived acetyl-coA to palmitate indicated by m+(2n) iso-
shown in blue. Shown is mean and SD (n = 3).
iMonA for 24 hr then treated with vehicle control (NT), ZOL, or C75 for 48 hr was
r vehicle (BSA), BSA+geranylgeraniol (GGOH), or BSA-conjugated Oleate 24 hr
hown is mean and SEM (n = 5).
values were calculated by ANOVA.
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Figure 7. High Expression of N-Myc and
MondoACoregulatedMetabolic GenesCor-
relates with Poor Prognosis
(A) Model of Myc-MondoA cooperation in regula-
tion of cellular metabolism (left). Synthetic lethal
condition upon activation of Myc and MondoA
loss of function (right). Abbreviations: electron
transport chain, ETC; tricarboxylic acid cycle,
TCA; and reactive oxygen species, ROS.
(B) Kaplan-Meier survival analysis based on the
expression of selected Myc and MondoA-regu-
lated genes. Red, blue, and gray lines indicate the
survival probability of patient with high (top 20%),
low (bottom 20%), and intermediate (remaining
60%) cumulative expression of MLXIP, CAD,
TFAM, CBS, SCD, PFAS, SLC3A2, and SLC1A5,
respectively. Significance between the top and
bottom 20% was determined by Wilcoxon model.
LIHC, liver hepatocellular carcinoma; LUNG, lung
squamous cell carcinoma and lung adenocarci-
noma data sets combined; COAD, colon adeno-
carcinoma; LAML, acute myeloid leukemia; and
BRCA, breast invasive carcinoma. Gene data sets:
neuroblastoma (Oberthuer et al., 2006) and for
rest, TCGA (http://cancergenome.nih.gov).2013) attenuate cancer cell growth. Interestingly, we find that
oleate partially rescues these insults as well as apoptosis due to
MondoA suppression in cells with high Myc levels. Our study re-
veals the importance of lipogenesis in Myc-dependent metabolic
reprogramming and provides a rationale for the clinical evaluation
of lipogenesis inhibitors inMyc-drivenmalignancies. This is highly
relevant in light of the recent report of altered lipidomic profiles
induced by Myc in human lymphomas (Eberlin et al., 2014)
Importantly, in contrast to all other Myc network members,
Mondo proteins are ligand activated, because they sense
glucose-6-phosphate and other glycolytic intermediates
(McFerrin and Atchley, 2012; Peterson et al., 2010; Stoltzman
et al., 2008). Blocking the ability of MondoA to respond to
glucose may represent a therapeutic strategy targeting Myc-
driven tumors. In addition, a small molecule inhibitor of c-Myc-
Max heterodimerization has been described (Wang et al.,
2007), indicating the feasibility of developing inhibitors of
Mondo-Mlx heterodimerization.
Previous studies have clearly established functional antago-
nism between Myc and Mxd/Mnt proteins in the control of cell282 Cancer Cell 27, 271–285, February 9, 2015 ª2015 Elsevier Inc.behavior (Hooker and Hurlin, 2006). How-
ever, recent work demonstrating a role for
Mnt in Myc-driven tumor progression
(Link et al., 2012), in conjunction with
our report describing Myc-MondoA tran-
scriptional synergy, suggests a more
complex scenario in which an imbalance
among network members promotes
apoptosis.
How do N-Myc and MondoA coop-
erate to promote the transcription of
their metabolic gene targets? One possi-
bility involves simultaneous binding of
both N-Myc and MondoA to promoterscontaining multiple E-boxes for maximal gene expression.
Binding of c-Myc and either MondoA or ChREBP to the
LDHA and HKII (Sans et al., 2006) or PKLR (Zhang et al.,
2010) promoters has been described and we demonstrate
that both N-Myc and MondoA bind to the TXNIP promoter.
We also show that N-Myc activation promotes Mondo-Mlx
activity by altering the expression of MondoA and other
network members competing for the common heterodimeriza-
tion partner Mlx. Conversely, loss of MondoA may inhibit
N-Myc transcriptional activity by altering chromatin at
metabolic target gene promoters to abrogate N-Myc tran-
scriptional amplification (Lin et al., 2012; Nie et al., 2012). More-
over, in the absence of MondoA, the Mxd and Mnt proteins
may heterodimerize with Mlx and actively repress N-Myc/
MondoA target genes. These mechanisms are not mutually
exclusive and may operate in a cell type- and promoter-specific
manner.
Althoughmuch attention has been focused onMyc because of
its oncogenic activity, we propose that a full understanding of
Myc biology in both physiological and pathological contexts
will require an understanding of the biology and dynamics of the
Max/Mlx network as a whole.
EXPERIMENTAL PROCEDURES
A complete list of all techniques and reagents, such as enzyme inhibitors,
retroviral, and lentiviral vectors and in vitro functional assay are listed in the
Supplemental Experimental Procedures.
Xenograft
We resuspended 1 3 106 Tet21N cells in growth factor reduced, phenol red-
free BD Matrigel (Becton Dickinson) that was subcutaneously injected into
the flanks of nude athymic (nu/nu) mice (n = 10). Tumor volume was measured
every 2–3 days and mice were killed when tumor burden reached a total vol-
ume of 2.5 cm3. Tumors were dissected and aliquots were either frozen in
liquid nitrogen or fixed in formalin for further analysis. Immunistochemistry
analysis was performed in the Fred Hutchinson Cancer Research Center
Experimental Histopathology Core. The Fred Hutchinson Cancer Research
Center Institutional Animal Care and Use Committee approved all mouse
experiments.
Gene Expression Analysis
Whole genome expression analysis was performed using Illumina HumanHT-
12 v4 Expression BeadChip. Sample processing was performed at the Fred
Hutchinson Cancer Research Center Genomics Facility and data were submit-
ted to Gene Expression Omnibus (accession number of data set: GSE55538).
For details about data statistical analysis, see below.
Metabolomic Profiling
Cell processing: 48 hr after transfection, 1 3 106 cells were plated in a six-
well plate. After 24 hr, culture media were aspirated, cells were washed twice
in ice-cold water, and lysed in 1.5 ml of ice-cold 9:1 methanol:chloroform with
the plates placed on dry ice (approximately 75C) to quench metabolism.
After 5 min, cells were scraped and transferred into 1.5 ml tubes. Lysates
were centrifuged at 13,000 revolutions per minute for 10min and supernatants
were transferred to new vials and dried using a Speedvac at room tem-
perature. After reconstituting the dried samples in water and 1% formic
acid, they were subjected to liquid chromatography-MS analysis (see Supple-
mental Experimental Procedures). Metabolite levels were normalized to cell
number from parallel plates. For details about data statistical analysis, see
below.
Statistical Analysis
Statistical significance of all in vitro experiments was calculated by using
Graphpad Prism software with either a Student’s t test for comparisons of
only two conditions or ANOVA and a Bonferroni correction for multiple
comparisons. Gene expression data were run in triplicate with quantile
normalized and log-transformed values. Significance was determined by
Benjamin Hotchberg FDR-adjusted p < 0.05 according to the lumi package
using R version 3.0.1 (Du et al., 2008). Gene ontology enrichment was re-
ported for categories satisfying Benjamin Hotchberg adjusted p < 0.05
from the DAVID boinformatic database (Huang et al., 2009). Metabolite
data were normalized to the N-Myc OFF and siCtrl condition with log-trans-
formed Z scores. Metabolite pathway enrichment was performed using
Metaboanalyst (Xia et al., 2012) with metabolite sets having FDR-corrected
p < 0.05 deemed significant. Both gene and metabolite heatmaps show
median Z scores of each triplicate sample using Cluster and TreeView (Eisen
et al., 1998).
Kaplan-Meier Survival Curves
Kaplan Meier curves were calculated for gene expression data obtained
for neuroblastoma (Oberthuer et al., 2006) as well as breast invasive carci-
noma, lung squamous cell carcinoma and lung adenocarcinoma, colon adeno-
carcinoma, acute myeloid leukemia, and liver hepatocellular carcinoma
reported by The Cancer Genome Browser (Lopez-Bigas N et al., 2013) for
The Cancer Genome Atlas (additional details in Supplemental Experimental
Procedures).CSUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, two tables, a list of siRNAs, and a list of MRM transitions and
can be found with this article online at http://dx.doi.org/10.1016/j.ccell.2014.
11.024.
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